Business & Finance

Biopharmaceutical company announces plans to refocus resources

Published in Blood Weekly, January 26th, 2006

XTL Biopharmaceuticals Ltd. (XTL), a biopharmaceutical company developing drugs against hepatitis, announced that it is implementing an additional step in the company's business plan designed to refocus the company's resources on the development of its lead hepatitis C programs, XTL-6865.

XTL-6865 currently in a phase 1 clinical trial; XTL-2125 is pending the commencement of a phase 1 clinical trial.

The main component of the plan is a reduction in overall headcount of 13 employees, or approximately 25%. The workforce reduction is limited to employees based in the company's Rehovot, Israel, facility, and consists primarily of early stage research...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-01-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry